Home > Insider Trading > Filing (0000899243-22-021348)

Filing Details

Accession Number:: 0000899243-22-021348
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-06-07 16:36:15
Reporting Period:: 2022-06-03

Accepted Time:: 2022-06-07 16:36:15
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1808158	Repare Therapeutics Inc.	RPTX	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1589095	Versant Affiliates Fund V, L.p.	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No
1589097	Versant Venture Capital V, L.p.	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No
1589098	Versant Ophthalmic Affiliates I, L.p.	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No
1612235	Versant Venture Capital V (Canada), Lp	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No
1619297	Versant Ventures V Gp-Gp (Canada), Inc.	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No
1619298	Versant Ventures V, Llc	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No
1687880	Versant Venture Capital Vi, L.p.	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No
1716490	Versant Ventures V (Canada), L.p.	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No
1777652	Versant Ventures Vi Gp-Gp, Llc	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No
1777654	Versant Ventures Vi Gp, L.p.	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Disposition	2022-06-03	250,000	$12.25	2,344,451	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2022-06-03	438,795	$12.25	1,464,875	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2022-06-03	13,199	$12.25	44,065	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2022-06-03	14,611	$12.25	48,776	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2022-06-03	33,395	$12.25	111,484	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2022-06-06	614,315	$0.00	850,560	No	4	J	Indirect	See Footnote
Common Shares	Acquisiton	2022-06-06	132,692	$0.00	132,692	No	4	J	Direct
Common Shares	Disposition	2022-06-06	18,478	$0.00	25,587	No	4	J	Indirect	See Footnote
Common Shares	Acquisiton	2022-06-06	3,992	$0.00	136,684	No	4	J	Direct
Common Shares	Disposition	2022-06-06	20,454	$0.00	28,322	No	4	J	Indirect	See Footnote
Common Shares	Acquisiton	2022-06-06	4,419	$0.00	141,103	No	4	J	Direct
Common Shares	Disposition	2022-06-06	141,103	$0.00	0	No	4	J	Direct
Common Shares	Disposition	2022-06-06	46,753	$0.00	64,731	No	4	J	Indirect	See Footnote
Common Shares	Acquisiton	2022-06-06	10,099	$0.00	10,099	No	4	J	Indirect	See Footnote
Common Shares	Disposition	2022-06-06	10,099	$0.00	0	No	4	J	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	J	Indirect	See Footnote
No	4	J	Direct
No	4	J	Indirect	See Footnote
No	4	J	Direct
No	4	J	Indirect	See Footnote
No	4	J	Direct
No	4	J	Direct
No	4	J	Indirect	See Footnote
No	4	J	Indirect	See Footnote
No	4	J	Indirect	See Footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Shares	231,211	Indirect	See Footnote

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
Shares held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP, VV VI and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
Shares held by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
Shares held by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
Shares held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I"). VV V is the sole general partner of VOAF I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
Shares held by Versant Venture Capital V (Canada) LP ("VVC V (Canada)"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VVC V to its partners.
Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V.
Shares held by VV V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VAF V to its partners.
Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V.
Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VOAF I to its partners.
Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOAF I.
Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V, to its members.
Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VVC V (Canada) to its partners.
Represents a change in the form of ownership of VV V (Canada) by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V (Canada).
Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V (Canada), to its partners.
Shares held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.